Navigation Links
Competitive Tech Achieves OTCQX Listing Compliance
Date:11/21/2013

FAIRFIELD, Conn., Nov. 21, 2013 /PRNewswire/ -- Competitive Technologies, Inc., (OTCQX: CTTC) (CTI), a pain mitigation biotechnology company, was notified yesterday, Wednesday, November 20, 2013 at 2:24 EST that it had returned to good listing compliance with the OTCQX.

On June 3, 2013, CTI was notified of its non-compliance with the rules and ongoing obligations of a publicly traded OTCQX company as so delineated in Section 3.1.r.(i) of the OTCQX Rules of U.S. Companies. On or about September 27, 2013, Management requested a three month extension to rectify the compliance shortfall due to the fact that there was a new management team in place as of September 26, 2013, which had initiated a corporate reengineering initiative that would rectify the non-compliance issue in short order. OTC Markets verbally agreed to an extension deadline of December 2, 2013.

"Being back in compliance with the OTC Markets is an enormous weight lifted off of CTI's shoulders," said CTI President & CEO Conrad Mir. "The Street has responded well to the recent changes made in the Company, which has contributed to this achievement. We believe this re-compliance may greatly contribute our fourth quarter results."

About the CompanyCompetitive Technologies Inc., (CTI) is a biotechnology company developing and commercializing innovative products and technologies. CTI is the licensed distributor of the non-invasive Calmare® pain therapy medical device, which incorporates the biophysical "Scrambler Therapy"® technology developed to treat neuropathic and cancer-derived pain by Professor Giuseppe Marineo.

Forward-Looking StatementsCertain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance.  Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.Contacts:Competitive Technologies, Inc.JV Public RelationsConrad MirJanet VasquezPresident and CEOManaging Directorcmir@competitivetech.netjvasquez@jvprny.com  973.798.8882212.645.5498Scrambler Therapy®: www.scramblertherapy.org/english.htm
Calmare®: www.calmarett.com

www.competitivetech.net

 


'/>"/>
SOURCE Competitive Technologies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Competitive Tech Reports Third Quarter 2013 Results
2. Cambridge Semantics and Linguamatics to Host Webinar on Competitive Intelligence Using Semantic Analysis
3. A*STAR IHPC and IDA to Co-Develop Innovative Cloud-Enabled Technological Solutions for Local ICT Companies to be More Competitive
4. Cambridge Semantics to Present on Smart Data and Competitive Intelligence Informatics at 2013 Pharma CI Conference & Exposition
5. United Airlines and AltAir Fuels to Bring Commercial-Scale, Cost-Competitive Biofuels to Aviation Industry
6. PharmaLeaders: Generic Manufacturers Benchmark Report - Financial Benchmarking & Competitive Analysis of the Leading Generic Players in 2013
7. PharmaLeaders: Innovative Mid-Cap Biotechnology Benchmark Report - Financial Benchmarking, Pipeline Assessment & Competitive Analysis of Innovative Biotechs
8. Neurovascular/Interventional Neurology Market [Aneurysm Coils, Carotid Stents, Microcatheter, Microguidewire, Liquid Embolic Agents, Cerebral Angioplasty Balloons] - Global Trends & Competitive Analysis - 2017
9. Pre-Clinical Imaging (In vivo) Market - by Systems and Reagents - Competitive Analysis & Global Forecasts to 2017
10. Neurovascular/Interventional Neurology Market: Global Trends & Competitive Analysis - 2017
11. Foot & Ankle Devices Market (2012 – 2017) By Product Type (External Fixation, Internal Fixation, Joint Replacement, Prosthesis, Bracing) - Global Trends & Competitive Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Epic Sciences unveiled a liquid ... to PARP inhibitors by targeting homologous recombination deficiency ... new test has already been incorporated into numerous ... types. Over 230 clinical trials are ... including PARP, ATM, ATR, DNA-PK and WEE-1. Drugs ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal articles ... findings are the subject of a new article on the Surviving Mesothelioma website. ... blood, lung fluid or tissue of mesothelioma patients that can help point doctors to ...
(Date:6/23/2016)... WI (PRWEB) , ... June 23, 2016 , ... ... supplements, is pleased to announce the launch of their brand, UP4™ Probiotics, into ... for over 35 years, is proud to add Target to its list of ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology:
(Date:4/15/2016)... , April 15, 2016 ... the,  "Global Gait Biometrics Market 2016-2020,"  report to ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait biometrics ... of 13.98% during the period 2016-2020. ... angles, which can be used to compute factors ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
(Date:3/22/2016)... , PROVO and ... Newborn Screening Ontario (NSO), which operates the highest sample ... molecular testing, and Tute Genomics and UNIConnect, leaders in ... respectively, today announced the launch of a project to ... (NGS) testing panel. NSO has been ...
Breaking Biology News(10 mins):